This study evaluates the effects of ACTIMMUNE (IFN-γ1b) in children and adults with
intermediate osteoporosis. All participants will receive treatment with ACTIMMUNE for 12
months. The investigators hypothesize that ACTIMMUNE will be tolerated by participants for
the full 12 months and result in decreased disease severity.
Phase:
Phase 2
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Collaborators:
Horizon Pharma Ireland, Ltd., Dublin Ireland University of Minnesota University of Minnesota - Clinical and Translational Science Institute